MARKET

NWBO

NWBO

Northwest Bio
OTCMQB
0.714
+0.002
+0.28%
Closed 15:59 09/30 EDT
OPEN
0.719
PREV CLOSE
0.712
HIGH
0.730
LOW
0.710
VOLUME
564.66K
TURNOVER
404.27K
52 WEEK HIGH
2.150
52 WEEK LOW
0.386
MARKET CAP
740.58M
P/E (TTM)
4.735
1D
5D
1M
3M
1Y
5Y
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has received approval from the UK Medicines and Healthcare Products Regulatory Agen...
PR Newswire · 08/23 13:39
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for license of the manufacturing facility in Sawston, UK for commercial...
PR Newswire · 07/06 18:17
Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that yesterday on June 4, 2022, in the Industry Expert Theater during the ASCO 2022 conference, Dr...
PR Newswire · 06/06 01:23
Northwest Bio plunges after late-stage data for lead candidate in brain cancer
The shares of Northwest Biotherapeutics (OTCQB:NWBO) reached a 52-week low on Tuesday after the clinical-stage immunotherapy company announced a presentation with Phase 3 data for its lead asset DCVax-L in
Seekingalpha · 05/10 16:52
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic C...
PR Newswire · 05/10 14:19
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Gliobl...
PR Newswire · 05/04 15:35
If You Invested $1000 In Northwest Biotherapeutics 5 Years Ago, Here's How Much You Would Have Today
Northwest Biotherapeutics (OTC:NWBO) has outperformed the market over the past 5 years by 42.99% on an annualized basis producing an average annual return of 54.57%. Currently, Northwest Biotherapeutics has a market capitalization of $1.42 billion.
Benzinga · 05/03 15:03
Northwest stock rises 9% as company begins cancer vaccine production at UK facility
Northwest Biotherapeutics (OTCQB:NWBO +7.6%) began production of its first dendritic cell cancer vaccine for a compassionate use patient at its production facility in Sawston, U.K. The company said the milestone follows
Seekingalpha · 02/17 14:49
More
About NWBO
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company's lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.

Webull offers kinds of Northwest Biotherapeutics, Inc stock information, including OTCMQB:NWBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NWBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NWBO stock methods without spending real money on the virtual paper trading platform.